BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//132.216.98.100//NONSGML kigkonsult.se iCalcreator 2.20.4//
BEGIN:VEVENT
UID:20260222T050024EST-5727412iO2@132.216.98.100
DTSTAMP:20260222T100024Z
DESCRIPTION:JOINT CORE/EBOH EPI Seminar Series Winter 2026\n\nThe Seminars 
 in Epidemiology organized by the Department of Epidemiology\, Biostatistic
 s and Occupational Health at the 成人VR视频 School of Population and Global He
 alth is a self-approved Group Learning Activity (Section 1) as defined by 
 the maintenance of certification program of the Royal College of Physician
 s and Surgeons of Canada. Physicians requiring accreditation\, please comp
 lete the Evaluation Form and send to admincoord.eboh [at] mcgill.ca.\n\nMi
 reille Guillot\, MD\, MSc\, FRCPC\n\nAssistant Professor\, Department of P
 ediatrics\n	Faculty of Medicine - Universit茅 Laval\n\nWHEN: Monday\, FEBRUA
 RY 23\, 2026\, from 3:30-4:30pm\n	WHERE: Hybrid | 2001 成人VR视频 College\, Rm 
 1140 &\n	5252 boul. de Maisonneuve - 3rd floor\, Kitchen & Zoom\n	Note: Mire
 ille Guillot will be presenting from Universit茅 Laval\n\nAbstract\n\nVery 
 preterm neonates miss the critical third-trimester placental transfer of o
 mega-3 docosahexaenoic acid (DHA)\, prompting widespread interest in postn
 atal supplementation. DHA plays a critical role in retinal and cerebral de
 velopment and may help modulate inflammation and oxidative stress. Despite
  this strong biological rationale\, randomized trials of DHA supplementati
 on in this population have produced inconsistent results\, leading to unce
 rtainty regarding clinical benefits and risks. This presentation reviews t
 he evolving evidence on omega-3 supplementation in very preterm neonates\,
  focusing on key sources of heterogeneity across trials\, including dose\,
  timing\, outcome definitions\, and the balance between DHA and arachidoni
 c acid. Drawing on two decades of research and recent advances in evidence
  synthesis\, the presentation highlights implications for major neonatal a
 nd neurodevelopmental outcomes and outlines remaining knowledge gaps and p
 riorities for future studies aimed at informing clinical decision-making.
 \n\nLearning Objectives\n\nAt the completion of this talk\, attendees will
  be able to:\n\n\n	Understand the biological rationale for omega-3 (docosah
 exaenoic acid\, DHA) supplementation in neonates born very preterm\;\n	Revi
 ew the current evidence from randomized trials and meta-analyses evaluatin
 g omega-3 DHA supplementation in very preterm infants\, including potentia
 l benefits and risks\;\n	Identify key knowledge gaps and research prioritie
 s in omega-3 supplementation strategies for preterm neonates.\n\n\nSpeaker
  Bio\n\nDr Mireille Guillot is an Assistant Professor in the Department of
  Pediatrics\, a neonatologist\, and a clinician-scientist at the CHU de Qu
 茅bec鈥揢niversit茅 Laval. After completing her pediatric residency and neonat
 ology fellowship training\, she completed a research-intensive fellowship 
 in Neonatal Neurology at The Hospital for Sick Children\, University of To
 ronto. In parallel\, she completed a Master鈥檚 in Epidemiology at Universit
 y of Toronto.\n\nHer research focuses on identifying modifiable risk facto
 rs in the neonatal period\, including neonatal nutrition\, to improve brai
 n development and long-term outcomes in children born preterm. As an early
 -career investigator and FRQS Junior 1 research award recipient\, she is b
 uilding a rapidly expanding research program in close collaboration with e
 xperts in perinatology\, neurodevelopment\, hemodynamics\, and nutrition.
 \n
DTSTART:20260223T203000Z
DTEND:20260223T213000Z
SUMMARY:Omega-3 Supplementation in Preterm Neonates The DHA Dilemma: Why Tr
 ials Disagree\, How the Evidence Has Evolved\, and Where It Is Heading
URL:/epi-biostat-occh/channels/event/omega-3-supplemen
 tation-preterm-neonates-dha-dilemma-why-trials-disagree-how-evidence-has-e
 volved-371098
END:VEVENT
END:VCALENDAR